ArticleJournal of clinical & cellular immunology2012
PD-L1/PD-1 Co-Stimulation, a Brake for T cell Activation and a T cell Differentiation Signal.
Article in Journal of clinical & cellular immunology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed.
- Reimagining Oncologic Drugs in Atherosclerosis: Emerging Mechanisms and Therapeutic Potential.Biomedicines · 2025Review
- The role of α-hydroxybutyrate in modulating sepsis progression: identification of key targets and biomarkers through multi-database data mining, machine learning, and unsupervised clustering.Frontiers in pharmacology · 2025Article
- Development and Characterization of an Anti-PD-L1 Immunotoxin for Targeted Cancer Therapy.Current pharmaceutical biotechnology · 2025Article
- Identification of Specific Cell Surface Markers on Immune Cells of Squirrel Monkeys (Journal of immunology research · 2024Article
- Immune Checkpoint Inhibitors in Hepatocellular Carcinoma: Current Strategies and Biomarkers Predicting Response and/or Resistance.Biomedicines · 2023Review
- Mechanisms of Primary and Acquired Resistance to Immune Checkpoint Inhibitors in Patients with Hepatocellular Carcinoma.Cancers · 2022Review
- Primary and Acquired Resistance against Immune Check Inhibitors in Non-Small Cell Lung Cancer.Cancers · 2022Review
- Salt-inducible kinase 3 protects tumor cells from cytotoxic T-cell attack by promoting TNF-induced NF-κB activation.Journal for immunotherapy of cancer · 2022Article
- Combination therapy for mCRPC with immune checkpoint inhibitors, ADT and vaccine: A mathematical model.PloS one · 2022Article
- TGF-β1 Induces Immune Escape by Enhancing PD-1 and CTLA-4 Expression on T Lymphocytes in Hepatocellular Carcinoma.Frontiers in oncology · 2021Article
- Article
- Article
- CD1d highly expressed on DCs reduces lung tumor burden by enhancing antitumor immunity.Oncology reports · 2019Article
- Immunobiochemical Reconstruction of Influenza Lung Infection-Melanoma Skin Cancer Interactions.Frontiers in immunology · 2019Article
- Immune-checkpoint inhibitors for combating T-cell dysfunction in cancer.OncoTargets and therapy · 2018Review
- ILC2s regulate adaptive Th2 cell functions via PD-L1 checkpoint control.The Journal of experimental medicine · 2017Article
- Bioengineering of Artificial Antigen Presenting Cells and Lymphoid Organs.Theranostics · 2017Review
- Olfactory ecto-mesenchymal stem cells possess immunoregulatory function and suppress autoimmune arthritis.Cellular & molecular immunology · 2016Article
- Overcoming tumor immune evasion with an unique arbovirus.Journal of translational medicine · 2015Review
- Intratumoral administration of mRNA encoding a fusokine consisting of IFN-β and the ectodomain of the TGF-β receptor II potentiates antitumor immunity.Oncotarget · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
For T cell activation, three signals have to be provided from the antigen presenting cell; Signal 1 (antigen recognition), signal 2 (co-stimulation) and signal 3 (cytokine priming). Blocking negative co-stimulation during antigen presentation to T cells is becoming a promising therapeutic strategy to enhance cancer immunotherapy. Here we will focus on interference with PD-1/PD-L1 negative co-stimulation during antigen presentation to T cells as a therapeutic approach. We will discuss the potential mechanisms and the therapeutic consequences by which interference/inhibition with this interaction results in anti-tumour immunity. Particularly, we will comment on whether blocking negative co-stimulation provides differentiation signals to T cells undergoing antigen presentation. A major dogma in immunology states that T cell differentiation signals are given by cytokines and chemokines (signal 3) rather than co-stimulation (signal 2). We will discuss whether this is the case when blocking PD-L1/PD-1 negative co-stimulation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.